| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| bupivacaine hydrochloride | Injection, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 2/01/2026 |
| morphine sulfate pentahydrate | Tablet, modified release | 10 mg | Current | Unavailable | Manufacturing | 2/01/2026 |
| morphine sulfate pentahydrate | Tablet, modified release | 30 mg | Current | Unavailable | Manufacturing | 2/01/2026 |
| morphine sulfate pentahydrate | Tablet, modified release | 60 mg | Current | Unavailable | Manufacturing | 2/01/2026 |
| morphine sulfate pentahydrate | Tablet, modified release | 100 mg | Current | Unavailable | Manufacturing | 2/01/2026 |
| ciprofloxacin hydrochloride | Tablet, film coated | 555 mg | Anticipated | Available | Manufacturing | 2/01/2026 |
| olanzapine pamoate monohydrate | Injection, powder for | 931 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 2/01/2026 |
| olanzapine pamoate monohydrate | Injection, powder for | 690 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 2/01/2026 |
| olanzapine pamoate monohydrate | Injection, powder for | 483 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 2/01/2026 |
| bisoprolol fumarate | Tablet | 2.5 mg | Current | Limited Availability | Manufacturing | 2/01/2026 |
| exemestane | Tablet, sugar coated | 25 mg | Current | Limited Availability | Manufacturing | 2/01/2026 |
| phenobarbital | Tablet, uncoated | 30 mg | Current | Unavailable | Manufacturing | 2/01/2026 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Resolved | Available | Manufacturing | 2/01/2026 |
| quetiapine fumarate | Tablet, modified release | 460.52 mg | Resolved | Available | Manufacturing | 2/01/2026 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Resolved | Available | Manufacturing | 2/01/2026 |
| quetiapine fumarate | Tablet, modified release | 57.565 mg | Anticipated | Available | Manufacturing | 2/01/2026 |
| clevidipine | Injection, emulsion | 25 mg | Resolved | Available | Unexpected increase in consumer demand | 2/01/2026 |
| Pegvisomant | Injection, powder for | 10 mg | Anticipated | Available | Manufacturing | 2/01/2026 |
| amlodipine besilate~olmesartan medoxomil | Tablet, film coated | 6.935 mg~40 mg | Anticipated | Available | Manufacturing | 2/01/2026 |
| ondansetron | Tablet, orally disintegrating | 4 mg | Current | Limited Availability | Manufacturing | 2/01/2026 |
| latanoprost~timolol maleate | Eye Drops, solution | .05 mg/mL~6.83 mg/mL | Current | Unavailable | Manufacturing | 2/01/2026 |
| Semaglutide | Injection, solution | 1.34 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 2/01/2026 |
| dimethyl fumarate | Capsule, enteric | 240 mg | Resolved | Available | Manufacturing | 2/01/2026 |
| lamotrigine | Tablet, chewable | 100 mg | Resolved | Available | Manufacturing | 2/01/2026 |
| lamotrigine | Tablet, chewable | 200 mg | Resolved | Available | Manufacturing | 2/01/2026 |
| prucalopride succinate | Tablet | 1.321 mg | Current | Unavailable | Manufacturing | 2/01/2026 |
| prucalopride succinate | Tablet | 2.642 mg | Current | Unavailable | Manufacturing | 2/01/2026 |
| amphotericin B | Injection, powder for | 50 mg | Anticipated | Available | Manufacturing | 2/01/2026 |
| naltrexone hydrochloride | Tablet, film coated | 50 mg | Current | Unavailable | Manufacturing | 2/01/2026 |
| tofacitinib citrate | Solution | 1.62 mg/mL | Resolved | Available | Manufacturing | 2/01/2026 |
| aggregated albumin~Albumin~stannous chloride | Injection, powder for | 2.25 mg~.25 mg~.21 mg | Current | Unavailable | Commercial Changes / Commercial viability | 2/01/2026 |
| ciprofloxacin hydrochloride | Tablet, film coated | 873.32 mg | Current | Unavailable | Manufacturing | 2/01/2026 |
| carbidopa monohydrate~entacapone~levodopa | Tablet, film coated | 27 mg~200 mg~100 mg | Anticipated | Available | Manufacturing | 2/01/2026 |
| digoxin | Injection, solution | .25 mg/mL | Current | Unavailable | Manufacturing | 24/12/2025 |
| metoprolol tartrate | Injection, solution | 1 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/12/2025 |
| lidocaine | Spray, solution | 100 mg/mL | Anticipated | Available | Manufacturing | 24/12/2025 |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 1200000 USP Unit | Current | Limited Availability | Manufacturing | 24/12/2025 |
| silver sulfadiazine | Cream | 10 mg/g | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/12/2025 |
| silver sulfadiazine | Cream | 10 mg/g | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 24/12/2025 |
| barium sulfate | Suspension, powder for | 98.453 % w/w | Current | Emergency Supply Only | 24/12/2025 | |
| benzathine benzylpenicillin tetrahydrate | Injection, suspension | 600000 USP Unit | Current | Unavailable | Manufacturing | 24/12/2025 |
| ramipril | Tablet, uncoated | 2.5 mg | Resolved | Available | Manufacturing | 24/12/2025 |
| lidocaine hydrochloride | Injection, solution | 10 mg/mL | Anticipated | Available | Manufacturing | 24/12/2025 |
| lamotrigine | Tablet | 200 mg | Current | Unavailable | Manufacturing | 24/12/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Unavailable | Manufacturing | 24/12/2025 |
| terbutaline sulfate | Injection, solution | .5 mg/mL | Resolved | Available | Manufacturing | 23/12/2025 |
| erythromycin lactobionate | Injection, powder for | 1515 mg | Anticipated | Available | Manufacturing | 23/12/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 23/12/2025 |
| sulfamethoxazole~trimethoprim | Injection, concentrated | 80 mg/mL~16 mg/mL | Current | Unavailable | Manufacturing | 23/12/2025 |
| Choriogonadotropin alfa | Injection, solution | 250 microgram | Current | Limited Availability | Unexpected increase in consumer demand | 23/12/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Anticipated | Available | Manufacturing | 23/12/2025 |
| montelukast sodium | Tablet, chewable | 5.2 mg | Anticipated | Available | Manufacturing | 23/12/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 23/12/2025 |
| levetiracetam | Solution | 100 mg/mL | Current | Limited Availability | Manufacturing | 23/12/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 23/12/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 23/12/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 23/12/2025 |
| nimodipine | Tablet, film coated | 30 mg | Anticipated | Available | Manufacturing | 23/12/2025 |
| prazosin hydrochloride | Tablet, uncoated | 1.095 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/12/2025 |
| prazosin hydrochloride | Tablet, uncoated | 5.476 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 22/12/2025 |
| posaconazole | Suspension | 40 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 22/12/2025 |
| glimepiride | Tablet, uncoated | 2 mg | Current | Unavailable | Manufacturing | 22/12/2025 |
| minoxidil | Tablet, uncoated | 10 mg | Resolved | Available | Manufacturing | 22/12/2025 |
| midazolam | Injection, solution | 1 mg/mL | Current | Limited Availability | Manufacturing | 22/12/2025 |
| dantrolene sodium hemiheptahydrate | Injection, powder for | 20 mg | Anticipated | Available | Manufacturing | 22/12/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.512 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 22/12/2025 |
| calcium folinate hydrate | Tablet, uncoated | 18.6 mg | Anticipated | Available | Unexpected increase in consumer demand | 22/12/2025 |
| remifentanil hydrochloride | Injection, powder for | 1.097 mg | Current | Limited Availability | Manufacturing | 22/12/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 22/12/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 22/12/2025 |
| finasteride | Tablet, film coated | 5 mg | Current | Limited Availability | Manufacturing | 22/12/2025 |
| voriconazole | Tablet, film coated | 50 mg | Current | Unavailable | Manufacturing | 22/12/2025 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Current | Unavailable | Manufacturing | 22/12/2025 |
| lansoprazole | Tablet, orally disintegrating | 30 mg | Current | Unavailable | Manufacturing | 22/12/2025 |
| betahistine dihydrochloride | Tablet | 16 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/12/2025 |
| risperidone | Tablet, film coated | .5 mg | Current | Unavailable | Commercial Changes / Commercial viability | 22/12/2025 |
| olmesartan medoxomil~hydrochlorothiazide | Tablet | 40 mg~12.5 mg | Current | Limited Availability | Manufacturing | 22/12/2025 |
| solifenacin succinate | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 22/12/2025 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Limited Availability | Manufacturing | 22/12/2025 |
| metaraminol tartrate | Injection, solution | 19 mg | Resolved | Available | Manufacturing | 22/12/2025 |
| sunitinib | Capsule | 12.5 mg | Current | Unavailable | Manufacturing | 22/12/2025 |
| isotretinoin | Capsule, soft | 20 mg | Current | Limited Availability | Manufacturing | 22/12/2025 |
| sitagliptin hydrochloride monohydrate~metformin hydrochloride | Tablet, modified release | 56.685 mg~1000 mg | Current | Unavailable | Manufacturing | 22/12/2025 |
| mivacurium chloride | Injection, solution | 2.14 mg/mL | Discontinued | Unavailable | Manufacturing | 22/12/2025 |
| mefloquine hydrochloride | Tablet, uncoated | 274.09 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 22/12/2025 |
| carboplatin | Injection, solution | 450 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/12/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | .25 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 22/12/2025 |
| parecoxib sodium | Injection, powder for | 42.36 mg | Anticipated | Available | Manufacturing | 22/12/2025 |
| alprostadil | Injection, powder for | 20 microgram/mL | Current | Unavailable | Unexpected increase in consumer demand | 22/12/2025 |
| alprostadil | Injection, powder for | 40 microgram/mL | Current | Unavailable | Manufacturing | 22/12/2025 |
2026年1月4日